EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models

Santeri A Pakola, Nea Ojala, Tatiana V Kudling, James H A Clubb, Elise Jirovec, Mirte van der Heijden, Victor Arias, Lyna Haybout, Saru Basnet, Susanna Grönberg-Vähä-Koskela, Dafne C A Quixabeira, Joao M Santos und 7 weitere

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04072-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Santeri A Pakola und 18 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Oncolytic Virotherapy, B7-H1 Antigen, Adenoviridae. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jane ja Aatos Erkon Säätiö, HUCH Research Funds, Syöpäsäätiö.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is a cancer with dismal prognosis due to resistance to most current therapies. Although immunotherapy has improved the treatment of many solid cancers, pancreatic cancer remains resistant to immunotherapy due to immunosuppressive tumor microenvironment, limited lymphocyte infiltration and lack of neoantigens. Oncolytic adenoviruses are a possible solution to treatment resistance in PDAC due to their ability to elicit lymphocyte trafficking and epitope spreading. Herein, we tested if an oncolytic adenovirus encoding a variant interleukin-2 molecule (Ad5/3-E2F-d24-vIL2), could enable immune checkpoint inhibitor (ICI) therapy in PDAC when combined with chemotherapy. Rationale for Ad5/3-E2F-d24-vIL2 was tested in vitro, where increase in programmed death ligand 1 (PD-L1) expression was seen after virotherapy and chemotherapy. Expression of other B7 family proteins was characterized in mono- and co-culture settings of cancer cells, fibroblasts, and macrophages. The combination therapy of virotherapy, chemotherapy and ICI was characterized in freshly resected ex vivo pancreatic tumor samples. Combination of ICI with virotherapy showed increased interferon and chemokine production in samples, with expansion of cytotoxic CD8 + T cells seen by flow cytometry. In vivo evaluation of the triple combination therapy in a Syrian hamster model showed improved tumor growth control and overall survival, with concurrent increase in intratumoral lymphocytes during therapy. Animals cured with the therapy showed resistance to re-challenge with the same cell line, supportive of successful generation of anti-tumor immunity in the animals. The combination treatment of Ad5/3-E2F-d24-vIL2, chemotherapy, and checkpoint inhibition is a promising treatment modality to tackle treatment resistance in PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsOncolytic VirotherapyB7-H1 AntigenAdenoviridaeCarcinoma, Pancreatic DuctalInterleukin-2Oncolytic VirusesImmune Checkpoint InhibitorsAnimalsHumansMiceCell Line, TumorCombined Modality TherapyMesocricetus

Stichwörter der Autor:innen

Adenovirus, Pancreatic cancerCheckpoint inhibitorImmunotherapyOncolytic virusPD-L1

Substanzen

B7-H1 AntigenInterleukin-2Immune Checkpoint InhibitorsCD274 protein, human

Autor:innen und Institutionen

  • Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • TILT Biotherapeutics Ltd, Helsinki, Finland.
  • Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Department of Urology, Helsinki University Hospital, Helsinki, Finland.
  • Department of Gynecology and Obstetrics, Helsinki University Hospital, Helsinki, Finland.
  • Department of Surgery, Translational Cancer Medicine Research Program and ICAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Förderung

  • Jane ja Aatos Erkon Säätiö
  • HUCH Research Funds
  • Syöpäsäätiö
  • Sigrid Juselius Foundation
  • Finnish Red Cross Blood Service
  • TILT Biotherapeutics
  • University of Helsinki

Zitieren

APA

Pakola, S. A., Ojala, N., Kudling, T. V., Clubb, J. H. A., Jirovec, E., van der Heijden, M., Arias, V., Haybout, L., Basnet, S., Grönberg-Vähä-Koskela, S., Quixabeira, D. C. A., Santos, J. M., Cervera-Carrascon, V., Hemminki, O., Kanerva, A., Mustonen, H., Puolakkainen, P., Seppänen, H., & Hemminki, A. (2025). Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04072-6

Vancouver

Pakola SA, Ojala N, Kudling TV, Clubb JHA, Jirovec E, van der Heijden M, et al. Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04072-6

BibTeX
@article{Pakola2025,
  author = {Pakola, Santeri A and Ojala, Nea and Kudling, Tatiana V and Clubb, James H A and Jirovec, Elise and van der Heijden, Mirte and Arias, Victor and Haybout, Lyna and Basnet, Saru and Grönberg-Vähä-Koskela, Susanna and Quixabeira, Dafne C A and Santos, Joao M and Cervera-Carrascon, Victor and Hemminki, Otto and Kanerva, Anna and Mustonen, Harri and Puolakkainen, Pauli and Seppänen, Hanna and Hemminki, Akseli},
  title = {Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04072-6}
}
Kostenlos starten →